Fingerprint
Dive into the research topics of 'Efficacy and Safety of 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for Non-Hodgkin's Lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Efficacy and Safety of 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for Non-Hodgkin's Lymphoma
Research output: Contribution to journal › Article › peer-review
38
Scopus
citations